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Introduction The International Cancer Benchmarking 
Partnership demonstrated international differences in 
ovarian cancer survival, particularly for women aged 
65–74 with advanced disease. These findings suggest 
differences in treatment could be contributing to survival 
disparities.
Objective To compare clinical practice guidelines and 
patterns of care across seven high- income countries.
Methods A comparison of guidelines was performed 
and validated by a clinical working group. To explore 
clinical practice, a patterns of care survey was developed. 
A questionnaire regarding management and potential 
health system- related barriers to providing treatment was 
emailed to gynecological specialists. Guideline and survey 
results were crudely compared with 3- year survival by 
‘distant’ stage using Spearman’s rho.
Results Twenty- seven guidelines were compared, and 
119 clinicians completed the survey. Guideline- related 
measures varied between countries but did not correlate 
with survival internationally. Guidelines were consistent 
for surgical recommendations of either primary debulking 
surgery or neoadjuvant chemotherapy followed by interval 
debulking surgery with the aim of complete cytoreduction. 
Reported patterns of surgical care varied internationally, 
including for rates of primary versus interval debulking, 
extensive/‘ultra- radical’ surgery, and perceived barriers 
to optimal cytoreduction. Comparison showed that 
willingness to undertake extensive surgery correlated 
with survival across countries (r
s
=0.94, p=0.017). For 
systemic/radiation therapies, guideline differences were 
more pronounced, particularly for bevacizumab and PARP 
(poly (ADP- ribose) polymerase) inhibitors. Reported health 
system- related barriers also varied internationally and 
included a lack of adequate hospital staffing and treatment 
monitoring via local and national audits.
Discussion Findings suggest international variations 
in ovarian cancer treatment. Characteristics relating to 
countries with higher stage- specific survival included 
higher reported rates of primary surgery; willingness to 
undertake extensive/ultra- radical procedures; greater 
access to high- cost drugs; and auditing.
INTRODUCTION
Ovarian cancer is the sixth most common cancer 
among women and has the highest mortality rate of 
all gynecological cancers internationally.1 Previous 
findings from the International Cancer Benchmarking 
Partnership (ICBP) demonstrated that, while differ-
ences in stage at diagnosis for ovarian cancer partly 
explained the survival gap, differences in survival also 
existed within each stage of disease.2 This a global 
collaboration of clinicians, policymakers, researchers, 
and cancer data experts, seeking to explain cancer 
survival differences between high- income countries 
with comprehensive cancer registry coverage, similar 
national health system expenditure, and universal 
access to healthcare. The ICBP SurvMark-2 project 
recently demonstrated international differences in 
ovarian cancer survival within age and stage groups, 
particularly for older women (65–74 years) with 
advanced disease, where 3- year net survival ranged 
from 52% (Norway) to 29% (Ireland).3 Notwith-
standing improvements in ovarian cancer outcomes 
internationally,4 variations in age- and stage- specific 
survival suggest differences in treatment may exist.
Clinical practice guidelines are designed to ensure 
that patients receive optimal care, typically based 
on the best available evidence, and offer a way 
of exploring treatment differences by comparing 
recommendations internationally.5 One also investi-
gates patterns of care to explore how they align with 
HIGHLIGHTS
• International differences in ovarian cancer treatment may contribute to differences in stage- specific survival between 
countries.
• Differences were found in rates of primary surgery,willingness to undertake extensive/‘ultra- radical’ surgery, and in 
types of systemic therapies recommended across clinical guidelines.
• Differences in perceived barriers to providing optimal treatment were also reported.
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guideline recommendations and how they may be influenced by 
health system- related factors. Most women with ovarian cancer are 
diagnosed with advanced stage disease (III- IV), for which optimal 
treatment is cytoreductive surgery and chemotherapy. Surgical 
options consist of either primary debulking surgery, or neoadju-
vant chemotherapy followed by interval debulking and may involve 
extensive (‘ultra- radical’) procedures.6 Despite a lack of consensus 
regarding primary versus interval debulking, and lack of prospec-
tive evidence supporting extensive/ultra- radical surgery, the goal of 
surgery remains no residual macroscopic disease, which is associ-
ated with improved survival.7
Systemic therapies play an important role in ovarian cancer 
treatment, with the use of carboplatin and paclitaxel chemotherapy 
now well- established.8 Intra- peritoneal chemotherapy remains 
controversial due to toxicity and, despite early promise, later trials 
failed to show improved survival.9 Radiotherapy may also be used 
in specific types of ovarian cancer and for palliation of advanced 
disease.10 Choice of therapies has further evolved through BRCA- 
mutation testing and the success of poly (ADP- ribose) polymerase 
(PARP) inhibitors in clinical trials.11
Health system- related factors influence the type and quality of 
treatment patients receive. This includes resources needed for 
surgery, such as sufficient operating theater time and intensive care 
unit beds,12 13 funding for expensive anti- cancer drugs, and the use 
of national audits to inform change and improve outcomes.14 Due 
to the lack of uniform and robust clinical data available to directly 
compare clinical practices among different countries, we have 
used guidelines and a validated questionnaire to indirectly explore 
differences in patterns of care and how these relate to survival 
for women with ovarian cancer in seven high- income countries. 
This study is the first to compare international clinical practice for 
ovarian cancer treatment.
METHODS
A document search was performed using PubMed; guideline- 
specific databases (Guidelines International Network); and online 
government portals. Search terms included specific disease name 
and relevant jurisdiction (‘ovarian cancer treatment guidelines OR 
pathway in Canada’). Inclusion criteria were guidelines widely used 
in routine ovarian cancer treatment as validated by working group 
members from each country, and guideline revisions from the past 
20 years to highlight the frequency of updates over time. Infor-
mation was extracted for jurisdiction; organization(s); publication 
year(s); and treatment modality. A working group of 19 clinicians 
was formed to validate the guideline comparison and provide addi-
tional insight into clinical practice differences.
A questionnaire was developed based on a previous survey 
conducted by Farrell et al investigating changes in surgical practice 
for ovarian cancer in Australia and New Zealand15 and extended 
to include additional questions. The questionnaire consisted of 34 
questions divided into four sections: 1. respondent characteristics, 
2. surgical practice, 3. systemic therapy, and 4. health system- 
related factors, and was validated and tested by a clinical working 
group. The gynecological oncologists/specialist surgeons, medical 
oncologists, clinical oncologists, and general gynecologists were 
chosen to receive the questionnaire using existing local networks 
available to the working group members. Working group members 
identified distribution lists which included those actively involved 
in the treatment of ovarian cancer. Country- specific response 
rates were calculated by dividing the number of responses by the 
number of questionnaires distributed in each country. Denomina-
tors were either database confirmed or estimated by multiplying 
the number of centers treating ovarian cancer in the country by the 
approximate number of specialists in each center. Survey- specific 
response rates were also calculated using the number of responses 
from each country. All data were maintained in Microsoft Excel 
(version 1803).
In all tables, figures, and supplementary materials, countries are 
ordered using the latest 3- year survival figures (2010–2014) from 
highest (Norway, 57.2%) to lowest (Ireland, 44.8%).3 Comparisons 
of 3- year survival by ‘distant’ stage (2010–2014) were performed 
using Spearman's rho in R Studio (version 3.5.1). Information gath-
ered from guidelines and the survey relate to the current time period 
(~2019) and does not align with the 2010–2014 survival data.
RESULTS
Twenty- seven guidelines were identified (online supplementary 
material 1). Comparisons are presented by treatment modality with 
additional textual information in Table 1. Guideline measures were 
compared across countries (online supplementary table 1). Most 
countries had a single organization producing guidelines except the 
UK (n=6). The UK also had the most documents identified (n=9) 
and the most recently published guideline (2018). Denmark had the 
most revisions, updating the same guideline four times since 2003. 
When crudely compared, correlations between guideline meas-
ures and survival for each country were all non- significant (online 
supplementary figures). A total of 119 clinicians completed the 
patterns of care survey. Respondent characteristics are summa-
rized in Table 2. Country- specific response rates ranged from 100% 
(Norway) to 10% (Australia). Survey- specific response rates also 
varied between countries, ranging from 3% to 27% (for Ireland and 
Canada, respectively) (online supplementary table 2). Only survey 
results from sections 1 and 4 are reported here.
Surgery
Guideline recommendations for surgery remained consistent. 
All guidelines recommend surgical staging, including pelvic and 
para- aortic lymph node sampling either randomly or by resection 
of suspicious nodes. Danish guidelines also recommend system-
atic lymphadenectomy for early- stage disease. All guidelines 
containing surgical recommendations included the options of 
primary debulking surgery (unless contra- indicated) and neoadju-
vant chemotherapy followed by interval debulking, with the aim of 
complete cytoreduction, if feasible (online supplementary glossary 
of surgical terms). These guidelines also considered cytoreductive 
surgery for ‘relapsed’/‘recurrent’ disease depending on disease- 
free interval and patient performance status (results not shown).
When surveyed, clinicians reported differences in patterns of 
surgical care. Norwegian clinicians reported the highest rates of 
primary surgery in patients with advanced epithelial ovarian cancer, 
whereas those from the UK reported the lowest rates of primary 
and highest rates of interval surgery (Figure 1). In the same patient 
population, all Norwegian and Australian respondents either agreed 
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or strongly agreed with ultra- radical surgery, whereas clinicians 
from Canada and the UK agreed with ultra- radical surgery to a 
lesser extent, with some respondents either disagreeing or strongly 
disagreeing with this approach (Figure 2). When crudely compared, 
willingness to undertake extensive/ultra- radical surgery correlated 
with 3- year survival by distant stage (r
s
=0.94, p=0.017).
Clinicians across all countries reported ‘medical co- morbidities’ 
as a perceived barrier to achieving optimal debulking in patients 
with advanced disease. Norwegian clinicians were least likely to 
report data for an ‘older patient population’. UK clinicians reported 
‘a lack of supportive care (intensive care unit beds)’ more often 
than clinicians from other countries and were less likely to report 
‘non- resectable metastasis outside abdominal cavity’; a barrier 
frequently reported by clinicians elsewhere (online supplementary 
material 2).
Systemic/Radiation Therapy
All guidelines recommended six cycles of platinum- based chemo-
therapy consisting of carboplatin and paclitaxel, most additionally 
recommending docetaxel, gemcitabine, or liposomal doxorubicin 
in cases of hypersensitivity and/or allergy to paclitaxel (results not 
shown). Differences were seen in guideline recommendations for 
other types of systemic therapy. Canadian, Australian, and Scottish 
guidelines recommend intra- peritoneal chemotherapy, whereas 
Danish and other UK guidelines do not recommend it outside of 
clinical trials. Norwegian and New Zealand guidelines omit guid-
ance on intra- peritoneal chemotherapy. Norwegian, Australian, 
Danish, Canadian, and Scottish guidelines recommend considering 
bevacizumab, whereas guidelines from New Zealand and the UK 
(Wales and Northern Ireland) do not. PARP inhibitors, including olap-
arib and/or niraparib, were recommended in all countries except 
New Zealand. Most of these guidelines recommended PARP inhib-
itors as maintenance treatment for relapsed platinum- sensitive 
BRCA mutation- positive advanced ovarian cancer. Some more 
recent guidelines from the UK (2019) and Ontario, Canada (2018) 
also recommend olaparib in newly diagnosed advanced disease.
Differences in radiotherapy were found. Cancer Australia’s 
optimal care pathway states that “some women may benefit from 
radiation treatment”, and British Columbia guidelines recommend 
radiotherapy on an individual basis for clear cell ovarian cancer. 
Alberta’s guideline indicates that radiation oncologists should 
consider radiotherapy in the context of palliation for selected cases 
to improve local control. All other guidelines did not contain radio-
therapy recommendations.
Health System-Related Factors
Differences in perceived health system- related barriers to 
accessing optimal treatment were reported (Figure 3). Norwegian 
clinicians most commonly reported restrictions in prescribing 
high- cost medications. Canadian clinicians often reported a ‘lack 
of patient access to clinical trials’. From the UK, a ‘lack of hospital 
staffing’ was commonly reported followed by ‘delays in treatment’. 
In New Zealand, clinicians often reported a lack of resources and 
funding for second- line drugs. Clinicians from Australia, Canada, 
the UK, New Zealand, and Ireland also reported a lack of treatment 
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DISCUSSION
This study suggests international differences in ovarian cancer 
treatment. Differences were seen in guidelines measures, including 
the number of documents published and revisions made. Although 
these did not correlate with survival when crudely compared, further 
research exploring the complex relationship between international 
guidelines and outcomes is needed. Despite consistency across 
guidelines, reported surgical practices varied. While all guide-
lines recommend primary or interval debulking for patients with 
advanced disease, clinicians from countries with higher survival 
Table 2 Survey respondent characteristics
Category
Country, n (%)
Norway Australia* Denmark Canada UK New Zealand Ireland
Total, n 18 13 16 32 30 7 3
Age
  35–39 2 (11) 1 (8) 0 3 (9) 2 (7) 2 (29) 1 (33)
  40–49 2 (11) 3 (23) 6 (37) 14 (44) 10 (33) 1 (14) 0
  50–59 8 (44) 7 (54) 8 (50) 8 (25) 13 (43) 4 (57) 1 (33)
  60–69 6 (33) 2 (15) 2 (12) 7 (22) 5 (17) 0 1 (33)
  ≥70 0 0 0 0 0 0 0
Years in practice
  <5 4 (22) 2 (15) 6 (37) 4 (12) 5 (17) 2 (29) 1 (33)
  5–9 2 (11) 3 (23) 3 (19) 8 (25) 4 (13) 0 0
  10–14 0 3 (23) 4 (25) 5 (16) 4 (13) 1 (14) 0
  15–19 6 (33) 3 (23) 3 (19) 3 (9) 12 (40) 3 (43) 1 (33)
  >20 6 (33) 2 (15) 0 12 (38) 5 (17) 1 (14) 1 (33)
Specialty
  Gynecological oncologist/specialist surgeons 18 (100) 10 (77) 10 (63) 28 (87) 19 (63) 2 (28) 1 (33)
  Medical oncologist 0 3 (23) 5 (31) 4 (13) 6 (20) 5 (72) 2 (67)
  Clinical/radiation oncologist 0 0 0 0 3 (10) 0 0
  OBGYN 0 0 1 (6) 0 2 (7) 0 0
*Including clinicians from New South Wales, Western Australia, and Victoria only.
Figure 1 Survey question: 'What percentage of your patients with advanced epithelial ovarian cancer who had surgery 
underwent primary debulking followed by chemotherapy? What percentage underwent neoadjuvant chemotherapy followed by 
interval debulking?'. Median results presented for each country. n=number of respondents.
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(Norway and Australia) reported higher rates of primary debulking. 
Although complete primary debulking has been associated with 
higher survival in late- stage patients,16 a lack of consensus still 
exists, with an Australian retrospective study finding that an 
increasing shift towards interval debulking was associated with 
increased survival.17 Commentators argue that primary debulking 
should still be considered the treatment of choice for fit patients 
with advanced resectable disease, whereas interval debulking is 
more suitable for patients with poorer performance and nutritional 
status, who are more likely to develop post- operative morbidity 
and mortality.18 Furthermore, most guidelines did not explicitly 
recommend extensive/ultra- radica’ surgery and yet clinicians from 
higher performing countries were more likely than those from lower 
performing countries to agree with ‘ultra- radical’ surgery.
Norwegian clinicians were least likely to perceive age as a barrier 
to achieving optimal cytoreduction and Norway demonstrated the 
highest survival in elderly patients with distant stage disease. In the 
UK, where clinicians perceived a lack of supportive care, survival for 
these patients was lower. These barriers could make clinicians less 
willing to operate on some patients, instead preferring a palliative 
option. Patients with advanced ovarian cancer are more likely to 
have severe co- morbidities and higher mortality,19 and historically, 
elderly patients were shown to be less likely to receive compre-
hensive surgical treatment.20 A Dutch study recently found that 
older patients and those with advanced disease were significantly 
less likely to receive any cancer- directed treatment.21 Moreover, 
available resources and operating theater time may influence a 
surgeons’ ability to perform extensive surgery and could impact 
Figure 2 Survey question: 'To what extent do you agree with ‘ultra- radical’ surgery for patients with advanced ovarian cancer, 
either by referring them or performing the operation with your own team?'. n=number of respondents. Results compared 
against 3- year net survival in patients with ‘distant’ stage disease according to ICBP SurvMark-2 results (r
s
=0.94, p=0.017).
Figure 3 Survey question: 'What do you consider health system barriers to accessing optimal treatment in your patient 
population?' n=number of respondents.
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patient outcomes.13 Importantly, it is this sub- category of elderly 
patients with advanced disease where survival is lowest and where 
significant differences exist.3
Other factors affecting surgical outcome include centralization of 
services,22 patient selection, discussion at multidisciplinary meet-
ings and adequate pre- operative staging.23 It is noteworthy that the 
two lowest performing countries, New Zealand and Ireland, had 
not implemented centralization in the 2010–2014 time period.24 25 
Moreover, some higher and lower performing countries central-
ized around the same time, including Norway (1995),26 the UK 
(1999),27 and Denmark (2001),28 indicating that other factors could 
be playing a role within centralized services, including access to 
specialist surgery.29 Since surgical outcome is a key prognostic 
factor for women with advanced ovarian cancer,7 differences in 
surgical practice may be contributing to survival variations and 
warrant further investigation within countries.
Differences were found in recommended systemic therapies. 
Intra- peritoneal chemotherapy remains contentious, with recent 
trial results failing to show a survival benefit in women with 
newly diagnosed advanced ovarian cancer.9 Disparities in its use 
may also stem from issues associated with increased resources 
and catheter- related complications, and that to overcome these 
would require time and specialist training.30 The benefits of beva-
cizumab are debated since it is yet to demonstrate improvements in 
overall survival.31 Given international differences in national health 
services spending,32 inequalities in access to high- cost drugs 
like bevacizumab may reflect different levels of available invest-
ment. Bevacizumab is not recommended in some of the lowest 
performing countries (Wales, Northern Ireland, and New Zealand), 
as it is not funded. New Zealand’s funding decisions for new medi-
cines are taken by Pharmac, the national regulatory body who 
declined bevacizumab based on several decision criteria.33 The 
Cancer Drugs Fund in England and Scottish Medicines Consortium 
in Scotland fund bevacizumab for selected patients. PARP inhibi-
tors have shown survival benefit in patients with a BRCA mutation 
with relapsed disease and, as of December 2019, are now recom-
mended in all countries.34 Their recent introduction does not align 
with the 2010–2014 study period, but PARP inhibitors will probably 
influence future survival analyses.
Different health system- related barriers to providing optimal 
treatment were perceived by clinicians internationally. For example, 
restrictions to drug prescribing were reported in Norway. In a qual-
itative study, Norwegian oncologists recently described distrust in 
their centralized drug review process, which has led to inequities 
in drug availability due to the privatization of high- cost medica-
tions.35 In Australia, insufficient hospital staffing was reported as 
a perceived barrier to providing optimal treatment. This has been 
reported by Australian health professionals previously, relating 
to a lack of staff with specialized expertize outside metropolitan 
centers.36 Similarly, in New Zealand, where a lack of resources was 
reported, a previous clinical audit suggested inadequate theater 
space could be impacting patient waiting times and outcomes.28 
In Canada, a perceived lack of patient access to clinical trials was 
reported. This may correspond with previous findings describing 
the barriers faced by Canadian physicians when participating in 
clinical research.37
Moreover, clinicians from countries with higher survival, such as 
Denmark and Norway, were more likely to report having no barriers 
to providing optimal treatment, whereas clinicians from countries 
with lower survival often reported a lack of treatment monitoring 
(via national and/or local audit) as a perceived barrier. One example 
of a current national auditing system is the Danish Gynecological 
Cancer Database, which has collected data on all women with 
ovarian cancer treated at Danish hospitals since 2005.38 Another 
example is the introduction of Scotland’s quality performance 
indicators.39 National auditing for ovarian cancer has been recom-
mended as a method of investigating treatment disparities and 
informing quality improvements.13 Given challenges in comparing 
ovarian cancer treatment rates internationally, this study supports 
existing calls for improved data collection at local and national 
levels. This is particularly pertinent in countries with lower survival, 
where national audits are not routinely conducted, and highlights a 
key area of improvement for policy and practice.
We note some limitations in this study. We acknowledge low 
survey response rates from some countries, which may not reflect 
true patterns of care. Comparatively, in a review of international 
surveys for patterns of surgery in advanced ovarian cancer, 
response rates ranged from 30% to 81%.40 Discrepancies between 
country- and survey- specific response rates are also noted. Coun-
tries with higher denominators often had lower response rates, yet 
also received a larger number of responses. This has the potential 
to bias conclusions drawn from the survey about national practice 
patterns. Questionnaires were distributed to either membership 
societies or specialist hospital departments. Questionnaires distrib-
uted via society mailing lists were sent to a wider demographic 
of clinicians, some of whom may not have responded. Therefore 
some country- specific response rates may appear disproportion-
ately lower than others.
We were not able to determine the demographic characteris-
tics of non- responders and were not able to exclude responder 
bias. The varying responsibilities of specialists internationally may 
hinder the interpretation of survey results. Gynecological oncolo-
gists in certain countries cover both surgery and medical oncology 
(Norway and Canada), but in others provide specialist surgical care 
only (Denmark and the UK). The questionnaire did not ask clinicians 
what proportion of their practice is spent treating ovarian cancer, 
and some respondents may be treating fewer patients with ovarian 
cancer than others, potentially affecting the results.
Information was not collected on the willingness of clinicians not 
to operate on patients. Rates of patients receiving no treatment 
were also not accounted for. An existing study has shown that a 
large proportion of patients with ovarian cancer receive no treat-
ment at all, often because patients choose not to have treatment.23 
This group are likely to be older with more co- morbidities, have 
poorer outcomes, and could partly explain international survival 
variations. The guideline recommendations and survey results 
relate to the current time- period (~2019), which must be consid-
ered when comparing these findings with ICBP SurvMark-2 results 
(2010–2014).
Despite consistency across guidelines, surgical practice varied 
internationally, particularly in rates of primary versus interval 
debulking, views towards extensive/ultra- radical surgery, and 
perceived barriers to achieving optimal cytoreduction. These differ-
ences are probably due to a combination of patient, clinician, and 
health system- related factors. Given the importance of surgical 
outcome in survival for patients with advanced ovarian cancer, 
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differences in surgical practice could be a key driver of interna-
tional disparities. Differences in recommendations for systemic/
radiation therapies were apparent and may reflect inequalities in 
levels of investment available to health systems to fund expensive 
drugs. In an effort to internationally benchmark ovarian cancer 
treatment, we indicate certain characteristics relating to countries 
with higher stage- specific survival including higher reported rates 
of primary debulking; willingness to undertake ultra- radical proce-
dures; greater access to high- cost drugs; and auditing. Treatment 
differences noted between countries warrant further investigation 
at local levels to determine their severity and potential impact on 
patient outcomes, particularly for older women with advanced 
disease, and in countries with lower stage- specific survival.
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